Literature DB >> 35574508

Molecular docking analysis of penta galloyl glucose with the bcl-2 family of anti-apoptotic targets.

Karthick Dharmalingam1, Velvizhi Dharmalingam2, Satheesh Durairaj3, Praveen Sharma1, Selvaraj Jayaraman4, Sarita Choudhary1.   

Abstract

Apoptosis requires cellular proteins from the B-cell lymphoma 2 (BCL-2) family linked to breast cancer. Therefore, it is of interest to document the Molecular docking analysis data of penta galloyl glucose with the bcl-2 family of anti-apoptotic targets (Bcl-2, BCL-XL, Caspase 3, and Caspase 9). Data shows that Pentagalloyl glucose have optimal binding features with Bcl-2, BCL-XL, Caspase 3, and Caspase 9 proteins with binding energy of -8.6,-7,-7.5 and 4.4 kcal/mol respectively for further consideration in this context.
© 2021 Biomedical Informatics.

Entities:  

Keywords:  Breast cancer; apoptosis; molecular docking; penta galloyl glucose

Year:  2021        PMID: 35574508      PMCID: PMC9070626          DOI: 10.6026/97320630017861

Source DB:  PubMed          Journal:  Bioinformation        ISSN: 0973-2063


  17 in total

Review 1.  Apoptosis: a review of programmed cell death.

Authors:  Susan Elmore
Journal:  Toxicol Pathol       Date:  2007-06       Impact factor: 1.902

2.  Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance.

Authors:  Meenakshi Upreti; Elena N Galitovskaya; Rong Chu; Alan J Tackett; David T Terrano; Susana Granell; Timothy C Chambers
Journal:  J Biol Chem       Date:  2008-10-30       Impact factor: 5.157

Review 3.  Modulation of mitochondrial apoptosis by PI3K inhibitors.

Authors:  Simone Fulda
Journal:  Mitochondrion       Date:  2012-05-10       Impact factor: 4.160

Review 4.  [Programmed cell death comes in many flavors].

Authors:  Lauriane Cabon; Ana-Carolina Martinez-Torres; Santos A Susin
Journal:  Med Sci (Paris)       Date:  2013-12-20       Impact factor: 0.818

5.  Cell division cycle associated 1 as a novel prognostic biomarker and therapeutic target for oral cancer.

Authors:  Phung Manh Thang; Atsushi Takano; Yoshihiro Yoshitake; Masanori Shinohara; Yoshinori Murakami; Yataro Daigo
Journal:  Int J Oncol       Date:  2016-08-05       Impact factor: 5.650

Review 6.  Evading apoptosis in cancer.

Authors:  Kaleigh Fernald; Manabu Kurokawa
Journal:  Trends Cell Biol       Date:  2013-08-16       Impact factor: 20.808

7.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.

Authors:  D L Vaux; S Cory; J M Adams
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

8.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

Review 9.  Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.

Authors:  A W Roberts; Dcs Huang
Journal:  Clin Pharmacol Ther       Date:  2016-11-26       Impact factor: 6.875

10.  BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?

Authors:  Lesley-Ann Martin; Mitch Dowsett
Journal:  Cancer Cell       Date:  2013-07-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.